These novel drugs are composed of an EGFR ligand or EGFR-binding antibody and a cytotoxic agent.
Antisense oligonucleotides specific for the EGFR or EGFR ligand messenger ribonucleic acids (RNAs) may decrease EGFR expression, thus resulting in inhibition of proliferation and induction of apoptosis.